Coronavirus disease 2019 vaccines and relevant adverse reactions

E. Chung
{"title":"Coronavirus disease 2019 vaccines and relevant adverse reactions","authors":"E. Chung","doi":"10.4168/aard.2021.9.3.124","DOIUrl":null,"url":null,"abstract":"In order to overcome the global pandemic of the new pathogen, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), intensive research has been conducted to understand viral pathogenicity, establish effective treatment strategies, and develop vaccines against coronavirus disease 2019 (COVID-19). To prevent COVID-19, a variety of COVID-19 vaccines have been rapidly developed and are currently being administered worldwide. When developing new vaccines, monitoring for adverse events following immunization (AEFIs) has always been important, and some COVID-19 vaccines are particularly effective as new types of vaccines that have not been used before, thus attracting attention to AEFIs. Vaccine administration is carefully conducted while monitoring for AEFI that are being reported from time to time. AEFIs are largely divided into local reactions, systemic reactions, allergic reactions, and adverse reactions to specific diseases or disease- attributable events. In addition, it is classified according to causes, but it is very difficult to confirm the association with the vaccine. Anaphylaxis, which is a systemic reaction among serious allergic reactions, requires immediate treatment and may require testing to determine the cause. In order to increase the vaccination rate and secure herd immunity, there should be no fear of vaccination due to unidentified side effects. Therefore, monitoring of AEFIs is important and causal relationships must be well established based on reliable epidemiological investigations. Current data show that the benefits of a COVID-19 vaccine far outweigh the risk of AEFIs. Future studies should continue to understand the mechanisms and risk factors of identified adverse reactions.","PeriodicalId":7548,"journal":{"name":"Allergy, Asthma & Respiratory Disease","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy, Asthma & Respiratory Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4168/aard.2021.9.3.124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 2

Abstract

In order to overcome the global pandemic of the new pathogen, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), intensive research has been conducted to understand viral pathogenicity, establish effective treatment strategies, and develop vaccines against coronavirus disease 2019 (COVID-19). To prevent COVID-19, a variety of COVID-19 vaccines have been rapidly developed and are currently being administered worldwide. When developing new vaccines, monitoring for adverse events following immunization (AEFIs) has always been important, and some COVID-19 vaccines are particularly effective as new types of vaccines that have not been used before, thus attracting attention to AEFIs. Vaccine administration is carefully conducted while monitoring for AEFI that are being reported from time to time. AEFIs are largely divided into local reactions, systemic reactions, allergic reactions, and adverse reactions to specific diseases or disease- attributable events. In addition, it is classified according to causes, but it is very difficult to confirm the association with the vaccine. Anaphylaxis, which is a systemic reaction among serious allergic reactions, requires immediate treatment and may require testing to determine the cause. In order to increase the vaccination rate and secure herd immunity, there should be no fear of vaccination due to unidentified side effects. Therefore, monitoring of AEFIs is important and causal relationships must be well established based on reliable epidemiological investigations. Current data show that the benefits of a COVID-19 vaccine far outweigh the risk of AEFIs. Future studies should continue to understand the mechanisms and risk factors of identified adverse reactions.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2019冠状病毒病疫苗及相关不良反应
为应对新型病原体-严重急性呼吸综合征-冠状病毒-2 (SARS-CoV-2)的全球大流行,人们开展了大量研究,以了解病毒的致病性,建立有效的治疗策略,并开发针对2019年冠状病毒病(COVID-19)的疫苗。为预防COVID-19,各种COVID-19疫苗已迅速开发,目前正在全球范围内接种。在开发新疫苗时,免疫后不良事件监测(AEFIs)一直很重要,一些COVID-19疫苗作为以前未使用过的新型疫苗特别有效,因此引起了对AEFIs的关注。在监测不时报告的急性呼吸道感染时,认真进行疫苗接种。aefi主要分为局部反应、全身反应、过敏反应和对特定疾病或疾病归因事件的不良反应。此外,它是根据病因分类的,但很难确认与疫苗的关联。过敏反应是严重过敏反应中的一种全身性反应,需要立即治疗,并可能需要检测以确定病因。为了提高疫苗接种率和确保群体免疫,不应因不明副作用而害怕接种疫苗。因此,监测急性脑损伤是重要的,必须在可靠的流行病学调查的基础上建立良好的因果关系。目前的数据显示,COVID-19疫苗的益处远远超过急性脑梗死的风险。未来的研究应继续了解已确定的不良反应的机制和危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
31
期刊最新文献
An 8-year-old girl with drug hypersensitivity to first triptorelin acetate administration Cigarette smoke extract contributes to the inception and aggravation of asthmatic inflammation by stimulating innate immunity Clinical characteristics of congenital pulmonary airway malformation of the lungs: A single-center study Desensitization for the prevention of drug hypersensitivity Allergen sensitization trajectories in children with respiratory and allergic diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1